Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab Combinations vs Investigator's Choice in Relapsed or Refractory Multiple Myeloma
NCT06208150Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Jan 2024; status: active, not recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06208150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208150.